Display options
Cite
Shadman M, Deeg HJ. Hematopoietic Cell Transplantation for Older Patients with MDS. Mediterr J Hematol Infect Dis. 2014;6(1):e2014056doi: 10.4084/MJHID.2014.056.
Shadman, M., & Deeg, H. J. (2014). Hematopoietic Cell Transplantation for Older Patients with MDS. Mediterranean journal of hematology and infectious diseases, 6(1), e2014056. https://doi.org/10.4084/MJHID.2014.056
Shadman, Mazyar, and Deeg, H Joachim. "Hematopoietic Cell Transplantation for Older Patients with MDS." Mediterranean journal of hematology and infectious diseases vol. 6,1 (2014): e2014056. doi: https://doi.org/10.4084/MJHID.2014.056
Shadman M, Deeg HJ. Hematopoietic Cell Transplantation for Older Patients with MDS. Mediterr J Hematol Infect Dis. 2014 Sep 01;6(1):e2014056. doi: 10.4084/MJHID.2014.056. eCollection 2014. PMID: 25237469; PMCID: PMC4165501.
Copy Download .nbib Format: NLM
Share it on

Mediterr J Hematol Infect Dis. 2014 Sep 01;6(1):e2014056. doi: 10.4084/MJHID.2014.056. eCollection 2014.

Hematopoietic Cell Transplantation for Older Patients with MDS.

Mediterranean journal of hematology and infectious diseases

Mazyar Shadman, H Joachim Deeg

Affiliations

  1. Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, WA, USA, 98109-1024.

PMID: 25237469 PMCID: PMC4165501 DOI: 10.4084/MJHID.2014.056

Abstract

The incidence of myeloid malignancies, including myelodysplastic syndromes (MDS) increases with age. While several therapeutic modalities have been developed, for most of these patients the only treatment with curative potential is allogeneic hematopoietic cell transplantation (HCT). The development of reduced/low intensity transplant conditioning regimens allows to successfully transplant patients in their '60s and even '70s, although comorbidities may determine who does come to transplantation and who does not. Also, as many as half of the patients will develop graft versus host disease (GVHD), even with HLA matched donors, requiring therapy for extended periods of time, and GVHD and treatment with glucocorticoids is likely to impact the quality of life. Nevertheless, dependent upon disease stage at HCT, the presence of comorbidities and the regimen used, 30% to 50% of patients 60 years of age or older, may survive long-term cured of their disease. Future studies should focus on the incorporation of non-transplant modalities into the overall transplant approach, the prevention of GVHD, and the utilization of immunotherapy to reduce the incidence of relapse and GVHD and further improve overall transplant success.

References

  1. Lancet Oncol. 2009 Mar;10(3):223-32 - PubMed
  2. Proc Natl Acad Sci U S A. 2007 Jul 3;104(27):11406-11 - PubMed
  3. Annu Rev Pathol. 2013 Jan 24;8:277-302 - PubMed
  4. Semin Oncol. 2012 Dec;39(6):683-93 - PubMed
  5. Biol Blood Marrow Transplant. 2008 Nov;14(11):1217-25 - PubMed
  6. Blood. 2008 Oct 1;112(7):2681-6 - PubMed
  7. Haematologica. 2013 Mar;98(3):414-9 - PubMed
  8. Blood. 2005 Oct 15;106(8):2912-9 - PubMed
  9. Bone Marrow Transplant. 2010 Feb;45(2):255-60 - PubMed
  10. Leukemia. 2013 Jun;27(6):1275-82 - PubMed
  11. Blood. 2007 Oct 1;110(7):2744-8 - PubMed
  12. Bone Marrow Transplant. 2012 Apr;47(4):494-8 - PubMed
  13. Br J Haematol. 2011 Apr;153(1):76-82 - PubMed
  14. Nat Med. 2010 Jan;16(1):49-58 - PubMed
  15. Biol Blood Marrow Transplant. 2013 Mar;19(3):429-34 - PubMed
  16. J Clin Oncol. 2011 Jun 1;29(16):2240-6 - PubMed
  17. J Clin Oncol. 2013 Jul 20;31(21):2662-70 - PubMed
  18. J Clin Oncol. 2010 Jan 20;28(3):405-11 - PubMed
  19. Cancer. 2006 Apr 15;106(8):1794-803 - PubMed
  20. Blood. 2010 May 27;115(21):4157-61 - PubMed
  21. Biol Blood Marrow Transplant. 2014 Apr;20(4):549-55 - PubMed
  22. Curr Pharm Des. 2012;18(22):3170-9 - PubMed
  23. N Engl J Med. 2012 Mar 22;366(12):1090-8 - PubMed
  24. J Clin Oncol. 2010 Apr 10;28(11):1878-87 - PubMed
  25. Blood. 2012 Sep 20;120(12):2454-65 - PubMed
  26. Ann Intern Med. 2006 Mar 21;144(6):407-14 - PubMed
  27. Cancer. 2012 May 15;118(10):2659-64 - PubMed
  28. Blood. 2012 Dec 13;120(25):4945-51 - PubMed
  29. J Clin Oncol. 2007 Aug 10;25(23):3503-10 - PubMed
  30. Blood. 2004 Aug 15;104(4):961-8 - PubMed
  31. Nature. 2011 Sep 11;478(7367):64-9 - PubMed
  32. Blood. 2014 Apr 10;123(15):2333-42 - PubMed
  33. Biol Blood Marrow Transplant. 2011 Mar;17(3):341-50 - PubMed
  34. N Engl J Med. 2006 Oct 5;355(14):1456-65 - PubMed
  35. Cancer Control. 2011 Oct;18(4):222-36 - PubMed
  36. JAMA. 2011 Nov 2;306(17):1874-83 - PubMed
  37. Genes Chromosomes Cancer. 2013 Dec;52(12):1167-77 - PubMed
  38. N Engl J Med. 2012 Oct 18;367(16):1487-96 - PubMed
  39. Blood. 2010 Sep 30;116(13):2304-14 - PubMed
  40. Blood. 2008 Jan 1;111(1):86-93 - PubMed
  41. J Clin Oncol. 2011 May 20;29(15):1987-96 - PubMed
  42. Curr Opin Oncol. 2013 Mar;25(2):173-9 - PubMed
  43. Blood. 2012 Apr 12;119(15):3578-84 - PubMed
  44. J Clin Oncol. 2011 Aug 20;29(24):3322-7 - PubMed
  45. Blood. 2013 Nov 21;122(22):3616-27; quiz 3699 - PubMed

Publication Types

Grant support